Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT.

J Clin Oncol. 2009 Sep 10;27(26):4300-5. doi: 10.1200/JCO.2008.18.2501. Epub 2009 Jul 27.

2.

Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Jun;67(6):1160-7. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.

3.

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV.

J Clin Oncol. 2005 Oct 1;23(28):6992-8.

PMID:
16192586
5.
6.

Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.

D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH.

J Urol. 2004 Nov;172(5 Pt 2):S42-6; discussion S46-7.

PMID:
15535442
8.

The association between pre-operative PSA and prostate cancer-specific mortality in patients with long-term follow-up after radical prostatectomy.

Lewinshtein D, Teng B, Valencia A, Gibbons R, Porter CR.

Prostate. 2012 Jan;72(1):24-9. doi: 10.1002/pros.21402. Epub 2011 Apr 25.

PMID:
21520159
9.

Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.

Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Feb;67(2):204-9. doi: 10.1016/j.eururo.2014.09.017. Epub 2014 Oct 5.

PMID:
25294696
10.

Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.

Aizer AA, Chen MH, Hattangadi J, D'Amico AV.

BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.

11.
12.
13.

Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.

Nelson CP, Dunn RL, Wei JT, Rubin MA, Montie JE, Sanda MG.

Urol Oncol. 2003 May-Jun;21(3):213-8.

PMID:
12810209
14.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.

Urology. 2008 Jan;71(1):136-40. doi: 10.1016/j.urology.2007.08.028.

PMID:
18242382
15.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

16.

NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.

Moul JW, Sarno MJ, McDermed JE, Triebell MT, Reynolds MA.

Urology. 2014 Dec;84(6):1427-32. doi: 10.1016/j.urology.2014.07.059.

PMID:
25432832
17.

Fifteen-year mortality after radical prostatectomy: which factors are available for patient counselling?

Wæhre H, Vlatkovic L, Cvancarova M, Paus E, Fosså SD, Danielsen HE.

Scand J Urol. 2014 Apr;48(2):123-30. doi: 10.3109/21681805.2013.817483. Epub 2013 Jul 25.

PMID:
23885810
18.
19.

Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.

Gallina A, Maccagnano C, Suardi N, Capitanio U, Abdollah F, Raber M, Salonia A, Scattoni V, Rigatti P, Montorsi F, Briganti A.

BJU Int. 2012 Jul;110(2 Pt 2):E64-8. doi: 10.1111/j.1464-410X.2011.10762.x. Epub 2011 Nov 17.

20.

Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.

Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV.

Urology. 2006 Aug;68(2):342-7.

PMID:
16904449

Supplemental Content

Support Center